Bone Marrow Suppression; Teratogen
Bone Marrow Suppression: severe
Carcinogen in humans
Mutagen, Teratogen: Probable in humans
Infertility associated with this drug
Monitoring data
Perform weekly hematological testing to determine hemoglobin, total & differential leukocyte counts, & quantitative platelet counts. Perform WBC during the first 3 to 6 weeks of therapy, at 3 or 4 days after each weekly complete blood cell counts.
Patient counseling
Package inserts
Additional information
Updated: January 2018
Disclaimer: This information presents a SUMMARY of Black Box data from product information labeling and does not address additional warnings, precautions, or other important safety data in the product insert. Patient care decisions SHOULD NOT be made without reviewing the most recent product information insert, which may be obtained from the manufacturer. This table may not be complete as it was prepared using product information from package inserts. It is periodically updated with supplemental information from FDA safety alerts, the FDA labeling announcements, and new drug approvals.
Formweb is a product of Rpharmy, LLC.
Visit our website at rpharmy.com for more information on online formularies featuring Black Box Warnings.